OrthoPediatrics this week said it launched its ApiFix spinal deformity correction system in the U.S.
The ApiFix Minimally Invasive Deformity Correction (MID-C) system is a posterior dynamic deformity correction system for use in adolescent idiopathic scoliosis (AIS) patients. It is approved for use in adolescents with Lenke type 1 and Lenke type 5 curves of 40° to 60° and acts as an internal brace that is implanted unilaterally on the concave aspect of the curvature.
“ApiFix’s novel approach to correcting spinal deformity is a welcome medical advancement that has the ability to disrupt the continuum of care for scoliosis treatment in certain pediatric patients. Its elegant design and biomechanical considerations combined with the simplistic posterior approach is unmatched and provides superior technology for treating AIS. Now that the pause of elective surgeries due to COVID-19 is lifting, we look forward to initiating the commercial availability of the procedure in the United States and anticipate the first procedures to be performed in the coming weeks,” senior VP Paul Mraz said in a news release.
OrthoPediatrics acquired the ApFix system in April for $2 million in cash and nearly 1 million shares of OrthoPediatric’s common stock.
“We are excited to begin providing access for this game-changing technology to children in the U.S. who are dealing with progressive scoliosis. The ApiFix system fills a major treatment gap after failed bracing and offers a viable treatment alternative potentially allowing patients to avoid fusion surgery with what we believe to be the least invasive surgical procedure for correcting scoliosis available in the world,” VP of spine Jeff Smithey said.